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Abstract
Background: Sleep disturbances are often referred to as a hallmark and as core symptoms of post-traumatic stress
disorder (PTSD). Untreated sleep disturbances can contribute to the maintenance and exacerbation of PTSD
symptoms, which may diminish treatment response and constitute a risk factor for poor treatment outcome.
Controlled trials on treatment of sleep disturbances in refugees suffering from PTSD are scarce. The present
study aims to examine sleep-enhancing treatment in refugees with PTSD. We aim to assess if add-on treatment with
mianserin and/or Imagery Rehearsal Therapy (IRT) to treatment as usual (TAU) for PTSD improves sleep disturbances.
We will study the relation between sleep disturbances, PTSD symptoms, psychosocial functioning and quality of life.
Methods: The study is a randomised controlled superiority trial with a 2 × 2 factorial design. The study will include 230
trauma-affected refugees.
The patients are randomised into four groups. All four groups receive TAU – an interdisciplinary treatment approach
covering a period of 6–8 months with pharmacological treatment, physiotherapy, psychoeducation and manual-based
cognitive behavioural therapy within a framework of weekly sessions with a physician, physiotherapist or psychologist.
One group receives solely TAU, serving as a control group, while the three remaining groups are active-treatment
groups receiving add-on treatment with either mianserin, IRT or a combination of both.
Treatment outcome is evaluated using self-administered rating scales, observer ratings and actigraph measurements at
baseline, during treatment and post treatment. The primary outcome is subjective sleep quality using the Pittsburgh
Sleep Quality Index. Secondary outcome measures are objective sleep length, nightmares, PTSD severity, symptoms of
depression and anxiety, pain, quality of life and psychosocial functioning.
Discussion: This trial will be the first randomised controlled trial to examine sleep-enhancing treatment in trauma-affected
refugees, as well as the first trial to investigate the effect of IRT and mianserin in this population. Therefore,
this trial may optimise treatment recommendations for sleep disturbances in trauma-affected refugees. Based
on our findings, we expect to discuss the effect of treatment, focussing on sleep disturbances. Furthermore,
the results will provide new information regarding the association between sleep disturbances, PTSD symptoms,
psychosocial functioning and quality of life in trauma-affected refugees.
Trial registration: EudraCT registration under the name ‘Treatment of sleep disturbances in trauma-affected refugees
– a randomised controlled trial’, registration number: 2015-004153-40, registered on 13 November 2015.
ClinicalTrials.gov, ID: NCT02761161. Registered on 27 April 2016.
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Background
The numbers of forcibly displaced people reached
record-high numbers by the end of 2016, with a total of
65.6 million people being forcibly displaced worldwide
as a result of persecution, conflict, generalised violence,
and/or human rights’ violations. Approximately 22.5
million of these people became refugees. These numbers
are currently increasing every year, primarily due to the
conflict in Syria [1].
It is estimated that roughly 30% of the world’s refugees
suffer from post-traumatic stress disorder (PTSD) and
often of a more chronic form, compared to other popula-
tions suffering from PTSD [2–4]. Refugees are a heteroge-
neous group in terms of cultural background and country
of origin, but share the experience of being forcibly dis-
placed from their country of origin and in this matter dif-
fer from other groups being exposed to traumas, who
continue to live under familiar and safe conditions [5].
Refugees differ from populations with single or few trau-
matic experiences by often having experienced prolonged
and repeated traumas pre-migration, during migration
and continue to live under post-migration stressors, such
as uncertainty about asylum status and temporary resi-
dence, concern about their families still unsafe in their
home country, cultural and language difficulties, and per-
ceived discrimination and racism [2, 3, 6]. Clinical guide-
lines for treatment, derived from research on other
populations fail to account for the specific circumstances
experienced by refugees, and cannot be assumed to apply
to trauma-affected refugees in general [5–7].
Sleep disturbances
Sleep disturbances are often referred to as a hallmark and
as core symptoms of PTSD [8–13]. As many as 70–87% of
persons suffering from PTSD describe sleep disturbances
[8, 10, 11]. In a sample of 752 trauma-affected refugees
undergoing psychiatric treatment at Competence Centre
for Transcultural Psychiatry (CTP), Mental Health Ser-
vices in the Capital Region of Denmark, in the period
2008–2012, 99% reported sleep disturbances and recur-
rent nightmares [14].
Sleep disturbances comprise problems initiating and
maintaining sleep, nightmares, early awakening and,
consequently, reduced length and quality of sleep. In the
following, sleep disturbances refer to the above
described and not to the formal diagnoses of insomnia
disorder and nightmare disorder in the Diagnostic and
Statistical Manual of Mental Disorders-5 (5th edition;
DSM-5) [15].
Standard pharmacological and psychotherapeutic
treatments of PTSD often focus primarily on daytime
symptoms and rarely examine sleep-related outcomes [9,
13]. Sleep disturbances often persist post treatment. For
instance, as many as 48% of patients treated with
cognitive behavioural therapy (CBT) for PTSD reported
residual insomnia post treatment [12, 13, 16]. Untreated
sleep disturbances can contribute to the maintenance
and exacerbation of both sleep-related and non-sleep-
related PTSD symptoms [8, 9, 12]. Sleep disturbances
may also affect the efficacy of first-line PTSD treatment
and constitute a risk factor for poor outcome of psychi-
atric treatment. It has been argued that targeting sleep
disturbances in treatment may lead to the alleviation of
PTSD symptoms in general and accelerate PTSD recov-
ery [8–12, 17, 18].
Furthermore, sleep disturbances in PTSD are found to
be related to increased psychiatric comorbidity, includ-
ing alcohol use disorder, and poor health status [13].
Sleep disturbances have consequences not only for the
individual, by compromising social and vocational func-
tioning and quality of life, but also from a socioeconomic
perspective due to reduced productivity, increased
absence from work and increased rates of unemployment
and early retirement pensions [17]. Previous studies on
PTSD found that improved sleep was related to improved
global functioning although a causal relationship could
not be demonstrated [18].
There is a need for further research on sleep distur-
bances, nightmares and the relation between improved
sleep and global functioning and PTSD symptoms in
general [12, 13].
Treatment of sleep disturbances
A number of studies have been published on psycho-
therapeutic and pharmacological treatment of sleep
disturbances in populations suffering from PTSD,
such as war veterans, crime victims and sexual assault
survivors [10–13, 18, 19]. However, controlled trials
on sleep disturbances in refugees suffering from
PTSD are scarce [14].
Pharmacological treatment
A range of studies have evaluated pharmacological treat-
ment of PTSD. However, most studies did not evaluate
changes in sleep-related outcomes. Reviews on pharma-
cological treatment of sleep disturbances in PTSD have
concluded that antidepressants, benzodiazepines and
non-benzodiazepine hypnotics are not beneficial. Only
treatment with prazosin (a selective α-1-adrenergic re-
ceptor antagonist) has been found effective in more than
one randomised controlled trial (RCT) [10, 13, 18]. Pra-
zosin, however, is not marketed in Denmark and is not
available for treatment.
In an attempt to relieve sleep disturbances, benzodiaz-
epines and antipsychotics are often prescribed despite
side effects and uncertainty about long-term efficiency.
Benzodiazepine side effects include development of tol-
erance, risk of dependence, withdrawal symptoms and
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cognitive impairment [11]. Antipsychotic drugs have nu-
merous side effects including extrapyramidal symptoms,
sedation, glucose dysregulation and weight gain [10, 11,
17, 20].
Mianserin as a sleep-enhancing treatment Mianserin
is a noradrenergic and specific serotonergic antidepres-
sant and is known to be well tolerated. Beside its
antidepressant capacity, it has anxiolytic and sleep-
enhancing capacities. One of its few side effects is sed-
ation which, in this study, is used clinically to enhance
sleep. Histamine H1-inverse agonist (i.e. strong antihista-
mine effects) and alfa1-antagonist activity is thought to
be responsible for the sedative quality [21–23].
In a large-scale trial evaluating treatment of trauma-
affected refugees at CTP, treatment with sertraline and
add-on treatment with mianserin showed significant im-
provement of sleep-related items on self-reported ratings
(The World Health Organisation-Five Well-being Index
(WHO-5), The Harvard Trauma Questionnaire (HTQ)
and Hopkins Symptom Check List-23 (HSCL-25)), but
due to the study design it was not possible to evaluate
whether this was an effect of mianserin [4, 24]. An
academic literature review did not identify any other
studies in which people suffering from PTSD were
treated with mianserin [14]. There is thus a need for
further studies.
Psychotherapeutic intervention
Due to a high acceptability in patients and a lack of
side effects, CBT is recommended as both first-line
treatment of primary sleep disturbances, prior to
pharmacological treatment, and as first-line treatment
of PTSD [11, 17, 25]. Most studies on the psycho-
therapeutic treatment of PTSD have not evaluated
sleep-related outcomes [9, 13]. Current CBT for
PTSD does not focus on sleep disturbances [9, 13].
As a consequence, a number of psychotherapeutic in-
terventions targeting sleep disturbances and night-
mares have been developed. Cognitive Behavioural
Therapy for Insomnia in PTSD (CBT-I) and Imagery
Rehearsal Therapy (IRT) have shown promising re-
sults [13, 26–28]. A number of treatment manuals
exist for particularly IRT, which differ in content and
thus complicate comparison and identification of
active components of the treatments [13, 26, 29, 30].
Furthermore, there is a lack of studies with an active
treatment control group, studies examining predictors
of outcome and dismantling studies of treatment
components [13, 26, 28].
Imagery Rehearsal Therapy as sleep-enhancing
treatment IRT is an adapted CBT, in which the subject
rehearses a new and non-disturbing dream to replace
the nightmare. IRT has shown promising results in pa-
tients suffering from PTSD by improving sleep length
and quality and by reducing symptoms of PTSD, but
there is a lack of studies on IRT in trauma-affected refu-
gees [14, 31–36]. In 2015, CTP completed a pilot case
study on IRT focussing on compliance and acceptability.
Based on session attendance, compliance with the
methods used, and qualitative interviews about the pa-
tients’ experiences with IRT, the pilot study delineated
IRT as an acceptable treatment for this population. The
pilot study was planned as primarily qualitative and,
therefore, the low number of patients (n = 5) did not
allow for statistical analysis on outcome (Poschmann, I.:
Imagery Rehearsal Therapy. Unpublised material). Based
on experiences from the pilot study, CTP has developed
an IRT manual integrating IRT into CBT supervised
by a researcher who previously conducted studies on
IRT [37]. The IRT manual is available on the CTP
website: www.ctp-net.dk.
Research objectives and hypotheses
On the background of the two above-mentioned studies
from CTP and the absence of relevant or conclusive data
on the treatment of sleep disturbances in trauma-
affected refugees, the present study aims to examine
sleep-enhancing treatment in refugees with PTSD. We
hypothesise that add-on treatment with mianserin or
IRT to treatment as usual (TAU) will improve sleep
quality and sleep length as well as reduce the severity
and frequency of nightmares compared to TAU. Further-
more, we hypothesise that add-on treatment with mian-
serin and IRT to TAU will improve the same parameters
more than each add-on treatment alone. We hypothesise
that enhanced sleep quality and sleep length will be associ-
ated with attenuated PTSD symptoms and with improved
observer-rated functioning and self-rated quality of life.
The objectives of this trial are (1) to estimate treat-
ment effects of IRT and mianserin on sleep quality, sleep
length and nightmares compared to TAU at CTP (please
see description below), (2) to study the relation between
enhanced sleep, PTSD symptoms, observer-rated func-
tioning and self-rated quality of life and (3) to examine
predictors for positive treatment outcome.
Methods
The study is a randomised controlled superiority trial with
an allocation ratio of 1:1:1:1. The study has a 2 × 2 factor-
ial design. Please see Fig. 1: Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) diagram
for enrolment, allocation, follow-up and analysis. The
study will include approximately 230 trauma-affected
refugees.
The patients are randomised into four groups. All four
groups receive TAU (please see description below); one
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group receives solely TAU, serving as a control group; the
three remaining groups are active-treatment groups re-
ceiving add-on treatment with either mianserin, IRT or a
combination of both. The course of treatment is divided
into two phases: phase 1 (approximately 2 months) and
phase 2 (approximately 4–6 months).
For a description of treatment outcome, please see de-
scription below and Fig. 1: Schedule of enrolment, inter-
ventions and assessments.
Trial fidelity
Manuals are used in sessions with physicians, physio-
therapists and psychologists to establish shared standard
procedures. The manuals have been developed by CTP
with specific focus on treatment of trauma-affected refu-
gees and are available in Danish on the CTP website:
www.ctp-net.dk. All clinicians have been trained in the
use of their respective manuals.
In order to determine trial fidelity, patient attendance is
registered and after each consultation with a physician,
psychologist or physiotherapist, the topics addressed are reg-
istered, as well as the methods used during the consultation
and whether the patient has completed their exercises be-
tween sessions as planned. Whether topics of a social char-
acter dominated the session are also registered in order to
document obstacles for fidelity to the treatment manuals.
At the end of phase 1 and phase 2 the patients
have a blood sample taken to determine the plasma
level of mianserin, primarily to determine compliance.
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram for enrolment, allocation, follow-up and analysis
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Patients who have a concentration of zero in the first
blood sample will not be excluded.
Participants and study setting
Participants are recruited at CTP, a tertiary mental
health service outpatient clinic in the Capital Region of
Denmark where the trial is also based and data collected.
The majority of the trauma-affected refugees referred to
CTP are from Afghanistan, Ex-Yugoslavia, Iraq, Iran,
Lebanon and Syria. In previous studies, approximately
half of the participants had experienced torture and
comorbidity of depression was approximately 95% [4].
The majority of the patients speak very little Danish or
English. An interpreter is present during 60 and 70% of
the sessions. Some of the patients have no, or very little,
education and some are illiterate.
Inclusion criteria
 Adults (18 years or older)
 Refugees or persons who have been family reunified
with a refugee
 PTSD pursuant to the International Classification of
Diseases, 10th edition (ICD-10) research criteria
 Psychological trauma experienced outside Denmark
in the anamnesis. Trauma is imprisonment or
detention with torture (according to the UN
definition of torture) or acts of cruel, inhuman and
degrading treatment or punishment. Trauma can
also be organised violence, long-term political
persecution and harassment, or war and civil-war
experiences
 Sleep disturbances/Pittsburgh Sleep Quality Index
(PSQI) > 8
 Nightmares/HTQ score on nightmare item of ‘a
little’ or higher
 Signed informed consent provided
Exclusion criteria
 Severe psychotic disorder (defined as patients with
an ICD-10 diagnosis F2x and F30.1-F31.9). Partici-
pants are excluded only if the psychotic-like experi-
ences are assessed to be part of an independent
psychotic disorder and not part of a severe PTSD
and/or depression
 Current alcohol or drug use disorder (F1x.24-
F1x.26)
 Known neurodegenerative disorder (Alzheimer’s
disease, Parkinson’s disease, Lewy-body dementia)
 In need of admission to a psychiatric hospital
 Pregnant and breastfeeding women and women of
reproductive age who wish to conceive during the
project period
 Allergy towards the active ingredients or excipients
in mianserin
 Lack of informed consent provision
Pre-treatment assessment
All patients referred to CTP undergo a pre-treatment
assessment (the content of the assessment is not specific
for this trial). The pre-treatment assessment is planned
as two to three sessions of approximately 45 min with a
physician and consists of recording of the trauma his-
tory, the migration process, sociodemographic character-
istics (education, job, marital status, family and housing),
somatic and psychiatric medical history, handedness,
somatic examination as well as a clinical assessment.
Standardised diagnostic tools, such as part of Schedules
for Clinical Assessment in Neuropsychiatry (SCAN) [38]
and the ICD research criteria, are applied in the inter-
view. The informed consent is obtained from patients in
this pre-treatment assessment.
The intervention and the course of treatment
All four groups receive TAU (please see description
below). The groups receive the following treatment: (1)
TAU, (2) TAU and add-on treatment with mianserin ad-
ministered in sessions with a physician, (3) TAU and, in
phase 2, add-on treatment with IRT integrated in
manual-based CBT in sessions with a psychologist, (4)
TAU and, in phase 1 and 2, add-on treatment with
mianserin administered in sessions with a physician, and
in phase 2 add-on treatment IRT integrated in manual-
based CBT in sessions with a psychologist.
Phase 1 consists of weekly sessions of 45 min with a
physician (six sessions) and weekly sessions with a
physiotherapist (six sessions). Phase 2 consists of
monthly sessions with a physician (four sessions), weekly
sessions with a psychologist (16 sessions) and sessions
with a physiotherapist (two sessions).
Treatment as usual (TAU)
Treatment as usual (TAU) for trauma-affected refugees
at CTP is an interdisciplinary treatment approach cover-
ing a period of 6–8 months with medicine according to
standard at CTP (best clinical practice in the field),
physiotherapy, psychoeducation (including sleep hygiene
education and relaxation techniques) and manual-based
CBT.
Interpreters are present in sessions if needed and dur-
ing conduction of ratings as required. The interpreters
are all affiliated with CTP and are experienced in inter-
preting questionnaires, psychotherapy and psychoeduca-
tion consultations.
Physician Pharmacological treatment follows an algo-
rithm in the physician’s manual.
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According to this manual, sertraline is first-choice
antidepressant, venlafaxine second-choice antidepressant
and imipramine third-choice antidepressant. In a previ-
ous study at CTP, the effect of sertraline and venlafaxine
on sleep disturbances were found to be equal [39, 40].
When steady state is reached, we aim to keep co-
medication constant, but any clinically necessary
changes are allowed.
Many patients who are referred to CTP already receive
psychopharmacological treatment. When possible, pa-
tients gradually phase out other psychopharmacological
treatments, and treatment according to algorithm is ini-
tiated. Co-medication is allowed and all changes, which
are clinically necessary, are allowed and will be con-
trolled for in the analysis if necessary.
In addition to the pharmacological treatment, patients
receive psychoeducation in an individually adjusted
course, in which relevant topics are addressed, such as
knowledge of the disorders (PTSD, depression and anx-
iety), sleep (sleep hygiene education and relaxation tech-
niques), pain, concentration and memory as well as
exercise and lifestyle.
Psychologist Previously, at CTP, different psychotherapy
manuals have been used, based on various combinations
of Trauma-Focussed CBT (TF-CBT), Acceptance and
Commitment Therapy (ACT), mindfulness, stress man-
agement (SM) and cognitive restructuring. On the basis
of the experience with these previous manuals, a new
manual has been prepared based on CBT, but adapted to
the target group. In the following, therapy given on the
basis of this updated manual will be referred to as
manual-based CBT.
A preliminary psychological assessment is carried out
prior to manual-based CBT by the psychologist in one
or two sessions in order to assess reflective functioning
and plan the individual course of therapy.
Physiotherapist The focus of the sessions is on the abil-
ity to relax by following instructions in relaxation tech-
niques and the ability to create a mentally calm place.
The exercises include instructions in resting positions,
body scans, and other relaxation techniques combined
with breathing exercises. This is supported by exercises
in reducing existing pain. The sessions also include psy-
choeducation on sleeping habits concerning sleep and
daily routines.
Trial medication – mianserin Mianserin is initiated at
10 mg daily per os. The dose can be increased gradually
to a maximum dosage of 30 mg daily per os adjusted ac-
cording to effect and side effects.
At each session with the physician, the patients are
asked if they have taken their medication as prescribed,
and the dose of mianserin is registered.
Compliance is monitored by measuring the plasma
concentration.
Imagery Rehearsal Therapy (IRT) IRT is integrated in
six sessions of manual-based CBT.
The sessions consist of psychoeducation on disturbing
dreams, nightmares and sleep as well as exercises in cog-
nitive restructuring and imagination, enabling the pa-
tient to transform the disturbing dream or nightmare
into a new and non-disturbing dream. All psychologists
have been trained in this specific method described in
detail in the IRT manual.
Outcome
Treatment outcome is evaluated using both self-
administered rating scales and observer ratings (please see
Fig. 2: Schedule of enrolment, interventions and assess-
ments). All self-administered rating scales have been
translated into the relevant languages. The rating scales
applied have been validated in several languages as well as
cultural settings.
The primary outcome in this trial is sleep quality
measured on the Pittsburgh Sleep Quality Index
(PSQI) [41, 42]. Secondary outcome measures are
nightmares (the Disturbing Dreams and Nightmare
Severity Index (DDNSI) [43]), sleep length (actigraphy),
PTSD severity (Harvard Trauma Questionnaire (HTQ)
[44]), symptoms of depression and anxiety (Hopkins
Symptom Check List (HSCL-25) [45] and blinded
Hamilton depression and anxiety rating scales (HAM-A
and HAM-D) [46]), pain (Brief Pain Inventory short form
(BPI) [47, 48]), quality of life (WHO-5 [49]) and level of
functioning (Sheehan Disability Scale (SDS) [50], Global
Assessment of Functioning – Symptoms (GAF-S), and
Functioning (GAF-F) [51] and The World Health Organ-
isation Disability Assessment Schedule (WHODAS 2.0)
[52] (please see Fig. 2: Schedule of enrolment, interven-
tions and assessments).
Patients complete self-administered rating scales pre-
treatment (baseline), between phase 1 and 2, and post
treatment. Both psychologists and physicians take part
in regular training sessions to ensure high interrater reli-
ability in relation to observer ratings.
Blinded HAM-A and HAM-D observer ratings take
place at baseline, post treatment and at 6 months’
follow-up post treatment. HAM-A and HAM-D ratings
are carried out by assessors blinded to intervention
group and pre or post treatment. The outcome assessors
carrying out HAM-A and HAM-D are trained medical
students, who participate in regular training sessions to
ensure high interrater reliability.
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As a supplement to the subjective measures of sleep, all
patients are equipped with an actigraph to measure
objective sleep length for a period of 2 weeks at baseline
and for 2 weeks post treatment. The actigraphic
recordings are supplemented by sleep logs where patients
register subjective sleep length, sleep quality and
nightmares.
Primary outcome measure
 The Pittsburgh Sleep Quality Index (PSQI) is an
internationally applied and thoroughly validated
self-administered rating scale assessing sleep quality
and the severity of sleep disturbances. PSQI consists
of 19 items and measures seven components of
sleep: sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of
sleeping medications, and daytime dysfunction. The
component scores each has a range of 0–3 points
and they are added to yield one global PSQI score
(range of 0–21 points) which distinguishes good
sleep (PSQI total score ≤ 5) from poor sleep
(PSQI total score > 5) [41, 42].
Secondary outcome measurements
Self-administered rating scales
 The Disturbing Dreams and Nightmare Severity
Index (DDNSI) is an internationally applied and
thoroughly validated self-administered rating scale
assessing frequency and severity of nightmares [43]
 The Harvard Trauma Questionnaire (HTQ) is an
internationally applied and thoroughly validated
self-administered rating scale assessing the severity
of PTSD symptoms. The first 16 questions of the
HTQ, Part IV (symptoms part) are used covering all
PTSD criteria in accordance with ICD-10 as well
as DSM-IV [44]
 The Hopkins Symptom Check List-25 (HSCL-25) is
an internationally applied and thoroughly validated
self-administered rating scale with 25 questions
assessing the severity of anxiety (10 questions) and
depression (15 questions) symptoms. This is a short
version of the Symptom Checklist-90 (SCL-90) [45]
 The World Health Organisation-Five Well-being
Index (WHO-5) is a self-administered questionnaire
evaluating quality of life, consisting of five questions.
The questionnaire has been used to assess quality
of life in a number of psychiatric diagnostic groups
[53, 54]. In addition, the scale has been used to
assess overall treatment effects in the field of
psychiatry [49]
 The Sheehan Disability Scale (SDS) is a
self-administered rating scale measuring functional
impairment with regard to family, work and social
network using three visual analogue scales from 0
to 10. Evaluation of the scale has shown that it is
STUDY PERIOD
Enrolment/allocation Post-allocation
TIMEPOINT t0 t1 t2 t3
(baseline) 2-3 months 8-12 months
6 months 
post 
treatment
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
TAU
TAU + miansein
TAU + IRT
TAU + 
mianserin + IRT
ASSESSMENTS:
Sociodemographic
characteristics, 
somatic and 
psychiatric medical 
history
X
PSQI X X X X
DDNSI X X X
HTQ X X X X
HSCL-25 X X X
WHO-5 X X X
SDS X X X
BPI X X
RBDSQ X
WHODAS X X
GAF-F X X X X
GAF-S X X X X
SCAN X
Diagnostic 
interview PTSD X
Blinded HAM A + D X X X
Actigraph X X
*Blood sample 
mianserin 
concentration
X X
ASSESSMENTS by 
psychologist:
PEX-1 X
CMOTS X
WHODAS 2.0 
subscale on 
cognition
X
Locus of Control X
Level of Personality 
Functioning Scale X
Session Rating 
Scale X
Patient satisfaction 
survey X
* Only intervention groups receiving mianserin.
Fig. 2 Schedule of enrolment, interventions and assessments
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sensitive to treatment effects in psychiatric
patients [50, 55]
 The Brief Pain Inventory short form (BPI) is a
self-administered rating scale assessing severity of
pain, impact of pain on daily functioning, location of
pain, pain medications and amount of pain relief in
the past 24 h or the past week. The BPI has been
through psychometric and linguistic validation in
more than 20 languages [47, 48]
Observer ratings
 Global Assessment of Functioning – Symptoms
(GAF-S) and Functioning (GAF-F) are numeric
observer rating scales used to assess the degree of
psychiatric symptoms and global functioning in
adults [51]
 The World Health Organisation Disability
Assessment Schedule (WHODAS 2.0) is an observer
rating scale used to measure health and disability
across cultures [52]
 The Hamilton anxiety and depression scales
(HAM-D and HAM-A) are observer rating
scales assessing depression and anxiety using
semi-structured interviews. The scales have been
used widely in psychiatric research including on
trauma-affected refugees [39, 53, 56–58]
 The CTP Predictor Index was developed in relation
to a previous trial at CTP to rate the psychosocial
resources of the patients [39, 59]. In this trial, the
index presented promising results as a predictor of
treatment outcome. The index was subsequently
adjusted according to the experiences in this
previous trial by dividing one predictor
(employment status) into three predictors
(employment status, daily activity and patient-
perceived economic situation). Furthermore, one
predictor (education) was removed. The rating
consists of 16 potential predictors: five rated by the
physician, five rated by the psychologist, and six
rated by the social worker. The predictors concern
the patients’ past, chronicity of mental health
problems, pain, treatment motivation, prerequisites
for engaging in psychotherapy as well as social and
economic situation. Each potential predictor is rated
according to pre-defined criteria. The physician,
psychologist and social worker complete the index
during their first session with the patient [39, 40]
Sleep and dream variables
 An Actigraph is a watch-like device worn on the
wrist measuring movement and amount of light.
The actigraphic recording can be used to distinguish
between periods of being awake and periods of sleep.
The actigraph measurements can be used to
estimate total sleep duration, sleep duration in
daytime and daily routines [60, 61]
 The REM Sleep Behaviour Disorder Screening
Questionnaire (RBDSC) is a self-administered
questionnaire with 10 items, assessing sleep
behaviour using ‘yes’ or ‘no’ questions. It has been
developed to assess the most prominent clinical
features of REM Sleep Behaviour Disorder [62]
Psychologist assessment
 The Psychotherapy Preferences and Experiences Scale
(PEX1) is a self-administered rating scale measuring
preferences and experiences of psychotherapeutic
interventions. It consists of 25 questions [63]
 The Client Motivation for Therapy Scale (CMOTS)
is used as a semi-structured interview assessing
motivation for therapy [64, 65]
 The World Health Organisation Disability
Assessment Schedule (WHODAS 2.0) subscale on
cognition is an observer rating scale with six
questions used to assess concentration, memory,
problem solving, learning and communication [52]
 Locus of Control (LOC) is used in an adapted scale
to assess the degree to which people believe that
they have control over their own lives [66]
 The Level of Personality Functioning Scale (LPFS)
is an observer rating scale used to assess
personality-related functioning with reference
to the normal personality [15]
 The Session Rating Scale (SRS V.3.0) is a
self-administered rating scale used to evaluate the
session [67]
Mental state assessment
 In each session with a physician, the patient’s
condition is assessed through a standardised clinical
examination covering 14 parameters such as mood,
suicidality and psychotic symptoms
Patient satisfaction survey
After the evaluation interview, the patient fills in a ques-
tionnaire on satisfaction with treatment. The question-
naire has 15 questions. Each item assesses to which
degree respondents were satisfied with different aspects
of the treatment program.
Other variables measured to evaluate trial medication
adverse events
The patients are asked about adverse events (AEs) in
each session with a physician. Adverse events are
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registered. From the patient being randomised and until
the patient stops participation in the trial, Each serious
adverse event (SAE), serious adverse reaction (SAR) and
suspected unexpected serious adverse reaction (SUSAR)
is registered in accordance with definitions and current
legislation by the Danish Medicines Agency. Orifarm
summary of product characteristics is used for mianserin
as a reference document to assess whether an AE or ad-
verse reaction is unexpected. Planned hospitalisation is
not considered a SAE. In addition, all discomfort in con-
nection with psychotherapy is registered.
Randomisation
The actual randomisation procedure is carried out as
follows: the randomisation sequence was computer gen-
erated by the Department of Biostatistics at the Univer-
sity of Copenhagen with allocation sequence with block
size unknown to the investigator. This department is not
otherwise involved in the research project. The Depart-
ment of Biostatistics at the University of Copenhagen
drew up a randomisation list. A person, who was neither
associated with the treatment nor the management of
the trial converted the randomisation list into sealed, se-
quentially numbered envelopes. The randomisation list
is kept at the Department of Biostatistics.
Two secretaries not involved in the daily work at CTP
manage the envelopes.
When a patient is found to be eligible for inclusion
and has signed informed consent, the physician contacts
the secretary mentioned above. The secretary opens the
envelope and informs the physician about the assigned
intervention group. The physician immediately notes the
assigned intervention group on the patient record. The
secretary notes the date of birth of the randomised
patient on a randomisation list in order to enable back-
tracking of the randomisation process. In the following
session, the physician informs the patient about the
assigned intervention.
The randomisation is stratified by gender.
Blinding
Blinding of patients and clinicians is not possible due to
the different nature of the treatment interventions.
However, blinded raters perform the HAM-A and
HAM-D ratings pre and post treatment.
Data assessment and data analysis will be performed
blinded.
Statistics
Power calculations and size of material
The primary outcome is PSQI. In previous trials, the Min-
imal Clinically Important Difference (MCID) on PSQI was
considered 2.5 scale points. This trial aims to detect a clin-
ically important difference between TAU and add-on
treatment and not merely a statistically significant differ-
ence and hence MCID was set to 2.5 scale points on the
PSQI and the within-groups standard deviation was set to
3 scale points [68]. With a power of 90% and alpha 0.05
we estimated a sample size for each group of 32 and a
total of 128. Based on the completion rate in previous tri-
als at CTP, 75–80% of the patients were estimated to
complete the treatment [53, 59]. Due to the expected large
dropout, a formula (k = 1/(100% − dropout%)2) calculating
the enhanced number of patients needed in each group
was used. We increased the number of patients included
with a factor k = 1/(100% − 25%)2 = 1.78 × 128 and
consequently estimated a total sample size of 228 patients.
The trial will be stopped when approximately 230
patients have completed the trial.
Dropout analysis
Dropout analysis is based on the patients who attend the
pre-treatment assessment.
The patients will be compared with the patients who
were excluded at the pre-treatment assessment on a
number of dimensions in order to identify possible
systematic selection bias.
The patients included in the trial, but who eventually
drop out and do not complete the trial, will be analysed
using intention-to-treat analysis. In addition, completer
analyses will be carried out.
Data processing
The study population is expected to score very highly on
PSQI, which means that even a significant change will
not necessarily bring the score under cut-off values.
Hence, the primary endpoint PSQI should be analysed
as a quantitative variable. Most outcomes are suitable
for linear regression, factorial 2 × 2 analysis of variance
(ANOVA) analysis with and without relevant covariates
and Full Information Maximum Likelihood (FIML) ana-
lyses (to handle missing data).
In order to analyse changes over time, we will calcu-
late differences between baseline and follow-up scores.
We will analyse potential predictors of outcome by lin-
ear regression and by logistic regression.
We plan a number of explorative subgroup analyses
including age, gender, average score on PSQI and HTQ
in an attempt to isolate predictors of positive outcome.
Actigraphy data will be analysed using standardised
software-implemented algorithms of sleep continuity pa-
rameters as well as calculation of more specific markers
of circadian stability.
Publications
Positive as well as inconclusive or negative results will
be published.
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Three publications are planned corresponding to the
three purposes of the study: (1) treatment effect on sleep
disturbances comparing mianserin, IRT and a combin-
ation of both, (2) the relation between enhanced sleep,
PTSD symptoms, physician-evaluated functioning and
patient-evaluated quality of life and (3) predictors of
treatment outcome.
If the results cannot be published in a journal, they
will be published at www.clinicaltrials.gov or
www.clinicaltrialsregister.eu.
Trial results will be communicated to patients via
letter.
The Vancouver rules for authorship will be followed.
There will be no use of professional writers.
Discussion
The presentation of the current study protocol ‘Treat-
ment of sleep disturbances in trauma-affected refugees –
a randomised controlled trial’ is in accordance with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) 2013 Statement for clinical
trial protocols; please see Additional file 1.
This trial will be the first randomised controlled trial
to examine sleep-enhancing treatment in trauma-
affected refugees as well as the first trial to investigate
the effect of IRT and mianserin on sleep disturbances,
PTSD symptoms, functioning and quality of life in
trauma-affected refugees. No evidence-based treatment
of sleep disturbances in this population exists. Therefore,
this trial may optimise treatment recommendations for
sleep disturbances in trauma-affected refugees. Further-
more, the results will provide new information about the
association between sleep disturbances, PTSD symp-
toms, psychosocial functioning and quality of life in
trauma-affected refugees.
A limitation to the trial is that neither the patient
nor the clinicians are blinded to treatment groups.
Furthermore, the primary outcome measure, PSQI, is
a self-administered rating scale and this can be a
limitation due to over- or under-estimation of treat-
ment effect.
The treatment outcome, covering both subjective and
objective measures, allows for high-quality analysis. The
risk of biased effect estimates is reduced by blinded out-
come assessors for HAM-A and Ham-D and intention-
to-treat analysis. Furthermore, the blinded 6-month
follow-up is a strength of the trial.
Trial status
Screening for patients for this trial began on 15 March
2016. The first patient was included on 12 May 2016. In-
clusion is expected to continue until 31 December 2017.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 123 kb)
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